en Radiation Biology Radiation Biology تحقيق بديع Original Research <div style="text-align: justify;"><span style="font-size:10pt"><span style="text-justify:newspaper"><span style="text-kashida-space:50%"><span style="line-height:119%"><span style="font-family:Calibri"><span style="color:black"><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Background</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Although radiotherapy (RT) is an important treatment modality for cervical cancer, it can cause cancer. However, the risk of second primary cancer (SPC) tends to be ignored during RT for cervical cancer. We analyzed the prevalence and incidence patterns of SPC in cervical cancer patients that underwent definitive RT.</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Materials and Methods</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:black"><span style="language:en-US">The insurance claims data of cervical cancer patients that underwent definitive RT from 2007 to 2012 were analyzed. Standardized incidence ratios (SIRs) were used to estimate the relative risks of SPC. In addition, </span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">odds ratios were estimated</span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> by unconditional Poisson regression and adjusted for age at cervical cancer diagnosis, chemotherapy, and comorbidities. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Results</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">Median patient age</span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">was 59.4 years. SIRs for bladder, ovary, and uterine cancer were 6.72 (95% confidence intervals (CI) 3.36&ndash;12.03, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="font-style:italic"><span style="language:en-US">p</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> < 0.001), 7.12 (95% CI 4.22&ndash;11.25, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="font-style:italic"><span style="language:en-US">p</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> < 0.0001), and 8.44 (95% CI 5.08&ndash;13.18, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="font-style:italic"><span style="language:en-US">p</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> < 0.001), respectively. The SIRs of all organs in the pelvic irradiation field were significantly increased. SIRs for breast and stomach cancer were 0.5 (95% CI 0.22&ndash;0.99, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="font-style:italic"><span style="language:en-US">p</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> = 0.0441) and 0.8 (95% CI 0.43&ndash;1.37, </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="font-style:italic"><span style="language:en-US">p</span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US"> = 0.5331), respectively. SIRs were not affected by chemotherapy, age, or comorbidities. </span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-style:italic"><span style="font-weight:bold"><span style="language:en-US">Conclusion</span></span></span></span></span></span><span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="color:#1f497d"><span style="font-weight:bold"><span style="language:en-US">:</span></span></span></span></span> <span lang="en-US" style="font-size:9.0pt"><span style="font-family:Calibri"><span style="language:en-US">RT increases the incidence of SPC in cervical cancer patients. In particular, SPC rates of organs in the irradiation field were higher than those of organs outside the irradiation field. If SPC risk were quantified with respect to irradiation dose, it could be utilized in clinical practice.</span></span></span></span></span></span></span></span></span></div> Cervical cancer, second primary cancer, radiotherapy. 551 544 http://ijrr.com/browse.php?a_code=A-10-1-944&slc_lang=en&sid=1 I. Seo 7900319475328460021908 7900319475328460021908 No Departments of Microbiology and Radiation Oncology, School of Medicine, Dongguk University, Gyeongsangbuk-do, Republic of Korea H. Jang opencagejhs@gmail.com 7900319475328460021909 7900319475328460021909 Yes Departments of Radiation Oncology, School of Medicine, Dongguk University, Gyeongsangbuk-do, Republic of Korea